Regeneron Executive Discusses AI in Drug Development
Regeneron's George Yancopoulos shared perspectives on the role of artificial intelligence in laboratory activities and drug development timelines.
Stocks · News reference
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DZ Bank Adjusts Price Target on Regeneron Pharmaceuticals
DZ Bank has updated its price target for Regeneron Pharmaceuticals, raising it to $1,067 from $900.
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.
Intellia Therapeutics and Regeneron Complete Enrollment in Phase 3 Trial of nex-z
Intellia Therapeutics, in collaboration with Regeneron Pharmaceuticals, has completed enrollment for the Phase 3 MAGNITUDE-2 clinical trial of nex-z for the treatment of ATTRv-PN.
Bank of America Adds Regeneron to 'Value 10' Portfolio
Bank of America Securities has added Regeneron Pharmaceuticals to its 'Value 10' portfolio for November, citing its inclusion in the firm's quantitative model for S&P 500 stocks.
Sanofi Ranked First in 2026 CNS Summit Digital Innovation Index
Sanofi has been recognized as the leader in the 2026 Digital Innovation Index, highlighting its integration of digital and AI technologies across its operations.